Polyneuron Extends Series A to CHF 36.5 Million with Additional CHF 14 Million
Sep 16, 2020•almost 5 years ago
Round Type
series a
Description
Polyneuron Pharmaceuticals AG, a clinical stage developer of a new class of antigen-specific polymers for the treatment of patients with serious autoimmune diseases, today announced a CHF 14 million extension of the Series A, bringing the total to CHF 36.5 million. HBM Healthcare Investments has joined the consortium of investors in the Series A, led by Sofinnova Partners, and which included New Enterprise Associates (NEA) and other private investors.
FundzWatch™ Score
81
Medium Activity
Buyer Intent Analysis
Get personalized insights on buying likelihood